Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Adolescent Suicide Risk
NCT04613453Phase 2Terminated
- Sponsor
- Yale University
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Yale University. Primary endpoint: Columbia-Suicide Severity Rating Scale at 48 hours. Started Jan 2022; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04613453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613453.